AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03207633 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive trans-magnetic stimulation (rTMS) on OFC
Description: Repetitive trans-magnetic stimulation (rTMS) on OFC
Study NCT03207633 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive trans-magnetic stimulation (rTMS)
Description: Sham repetitive trans-magnetic stimulation (rTMS)
Study NCT03559933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEPNS System
Description: PEPNS System therapy will be delivered periodically up to 48 hours or less if patient is no longer being mechanically ventilated.
Study NCT02800980 — intervention group
Intervention type: PROCEDURE
Intervention: Drainage and sclerotherapy.
Description: Lymphocele percutaneous / transvaginal drainage with a use of a vascular catheter followed by sclerotherapy.
Study NCT02800980 — intervention group
Intervention type: PROCEDURE
Intervention: Drainage alone.
Description: Lymphocele percutaneous / transvaginal drainage with a vascular catheter alone (without sclerotherapy).
Study NCT03625336 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: An MRI will be obtained utilizing 3 different MRI sequences
Study NCT01088620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 9 mg/kg BW will be administered IV every 3 weeks (q3w) for a maximum of four cycles.~In case of CR, PR or SD status at the end of the combination treatment, a panitumumab single drug treatment, consisting of 9 mg/kg BW administered every 3 weeks, will be performed until detection of disease progression.
Study NCT01088620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
Study NCT01088620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
Study NCT01088620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
Study NCT01088620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
Study NCT02209896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Reprieve system
Description: BlueWind Medical neurostimulator for the treatment of neuropathic pain
Study NCT02083406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800mg OZ439 prototype formulation 2
Study NCT02083406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800mg OZ439 prototype formulation 3
Study NCT02083406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 960mg PQP
Study NCT02930928 — intervention group
Intervention type: OTHER
Intervention: Accuracy of weight estimation
Description: Computer based comparison
Study NCT05151809 — intervention group
Intervention type: OTHER
Intervention: Clinical information
Description: The investigators will recruit PBC patients and collect important clinical information and laboratory investigation, together with biological samples.
Study NCT05297188 — intervention group
Intervention type: DEVICE
Intervention: ergonomic sleep mask
Description: Ergonomic sleep mask; It is a material that covers the eye and ear completely and can be adjusted according to the patient, can be washed and reused at 30 degrees after use, 95% cotton, 5% polyester structure and 100% light proof properties.
Study NCT02463526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization with Movement (MWM) condition/ Sham condition
Description: The treatment condition consists in the application of a posterolateral glide (MWM) in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. One hand will be placed over the scapula posteriorly while the thenar eminence of the other hand will be placed over the humerus head anterior aspect. A posterior glide will be applied to the humeral head. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. Sham condition will replicate treatment condition except for the hand positioning. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed.
Study NCT02463526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham condition/ Mobilization with Movement (MWM) condition
Description: The Sham condition consists in the application of a simulated anterior glide in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. The treatment condition will replicate treatment condition except for the hand positioning. The therapist will place one hand over the scapula posteriorly while the thenar eminence of the other hand will be placed over the anterior humerus head. A posterior glide will be applied to the humeral head.
Study NCT02566629 — intervention group
Intervention type: OTHER
Intervention: collect faeces from participants
Description: analyze the fecal microbiota community using 16S rDNA detection technique
Study NCT03107741 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Exercise
Description: Subjects in this group will receive three 1-hour conventional exercise training sections per week for 12 weeks
Study NCT03107741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi
Description: Subjects in this group will receive three 1-hour tai chi training sections per week for 12 weeks
Study NCT03796026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant 40 mg
Description: Seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.
Study NCT03796026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.
Study NCT03470402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RealRisks
Description: RealRisks is a web-based patient decision aid with modules on risk assessment, family history and breast cancer, genetic testing, and prevention options. Participants enter family history data into RealRisks, and RealRisks calculates 5-year breast cancer risk, lifetime breast cancer risk, and the probability of carrying a BRCA mutation. This information is then interactively presented to the participant. RealRisks facilitates the participant in identifying their intention to undergo BRCA genetic testing and the factors that are important to the participant in making this decision. RealRisks produces a summary of all of this information that the participant can print and take with her to a health care appointment.
Study NCT03470402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BNAV
Description: BNAV is a web-based decision support tool for healthcare providers with educational modules on genetic testing, chemoprevention, patient-centered care, and screening. BNAV also provides providers with a table outlining their enrolled patients' breast cancer risk, eligibility for genetic testing, and stated preferences.
Study NCT03470402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: iNYP
Description: Enrolled patients will have their eligibility for BRCA genetic testing flagged in iNYP, the hospital's portal for visualizing EHR data (standard practice).
Study NCT03470402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iNYP
Description: Enrolled patients will have their eligibility for BRCA genetic testing flagged in iNYP, the hospital's portal for visualizing EHR data (standard practice).
Study NCT03470402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Educational Material
Description: Enrolled patient participants will be sent standard educational brochures on genes and breast cancer and the CUMC breast cancer prevention clinic
Study NCT03470402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Educational Material
Description: Enrolled patient participants will be sent standard educational brochures on genes and breast cancer and the CUMC breast cancer prevention clinic
Study NCT03470402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-Risk Message
Description: Enrolled patient participants will receive a letter that informs them that they meet eligibility criteria for BRCA genetic testing, outlines prevention options, and recommends discussing genetic counseling referral with their health care provider (standard practice).
Study NCT03470402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Risk Message
Description: Enrolled patient participants will receive a letter that informs them that they meet eligibility criteria for BRCA genetic testing, outlines prevention options, and recommends discussing genetic counseling referral with their health care provider (standard practice).
Study NCT00130611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BNP measurement
Study NCT03220620 — intervention group
Intervention type: OTHER
Intervention: GDT
Description: individualized fluid therapy
Study NCT02406586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: Salsalate 750 mg
Study NCT00130611 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Clinical examination
Study NCT00130611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination
Study NCT01324362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Twice daily dosing
Study NCT01324362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP 100mcg
Description: Twice daily dosing
Study NCT01324362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP 250mcg
Description: Twice daily dosing
Study NCT01324362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP 500mcg
Description: Twice daily dosing
Study NCT01324362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSC 100/50mcg
Description: Twice daily dosing
Study NCT01324362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSC 250/50mcg
Description: Twice daily dosing
Study NCT01324362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSC500/50mcg
Description: Twice daily dosing
Study NCT00064792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin Susp.
Description: During the simvastatin phase of the trial, therapy will be initiated at 0.5 mg/kg/day for six weeks and then increased to 1.0 mg/kg/day if adverse side effects are minimal or absent.
Study NCT00064792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OraPlus
Description: During this trial and for two months prior, patients will be maintained on 150 mg/kg/day of dietary cholesterol (150 mg/ml in OraPlus) for the duration of the trial
Study NCT00682955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Sulphate
Description: 20 mg per day, Zinc Sulphate tablet has been given to subjects.
Study NCT00682955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Sulphate
Description: 20 mg per day of Zinc Sulphate in suspension form has been given to subjects.
Study NCT02406586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol 3.125 mg
Study NCT02406586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet
Study NCT00177255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 30 mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days.~Cycle 2 will begin on day 22.
Study NCT00177255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 825 mg/m2 bid (total daily dose 1650 mg/m2) will be administered orally for 14 days (days 1-14).~Each cycle will consist of 21 days.~Cycle 2 will begin on day 22.
Study NCT03991429 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Simultaneous functional MRI and urodynamic studies
Description: Double lumen 7 Fr MRI-compatible catheters will be placed in the bladder and rectum. A Phillips Ingenia 3.0T full body MRI scanner with standard 12 channel head coil will be used. Instructions to communicate using right hand signals representing full urge and voiding or attempt of voiding will be given. Signs will be shown to the patient when filling of the bladder is begun and when filling is stopped. Also, in order to keep our noise-to-signal ratio low, all stimulators including any extra visual stimuli and the UDS machine will be removed from the MRI scanner room. The filling and voiding cycle will be repeated up to 4 times in each patient. Bladder will be aspirated after each voiding. This algorithm will be performed before, and, 3 and 6 months following BOO procedure.
Study NCT03991429 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Each patient will provide a detailed history and undergo a complete physical examination. Each patient will have the following assessments: IPSS and Incontinence Severity Index (ISI), Patient Global impression of severity (PGI-S) and improvement (PGI-I), International Index of Erectile Function (IIEF-5), MRI Safety Screening Questionnaire.
Study NCT02406586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid 20%
Description: 24-hour infusion of Intralipid 20% solution at 20 mL/h (96 g/24 h)
Study NCT02406586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intralipid 20%
Description: 24-hour infusion of Intralipid 20% solution at 20 mL/h (96 g/24 h)
Study NCT02702115 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-318
Description: A single dose of each of the three components of SB-318 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.
Study NCT03991429 — intervention group
Intervention type: OTHER
Intervention: Post Void Residual (PVR), Uroflow and Bladder Diary
Description: Follow-up assessments: Uroflow and PVR assessment, bladder diary, and all questionnaires will be repeated in all patients at one, three, and six months.
Study NCT03991429 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urinalysis
Description: Urine sample
Study NCT00883441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insecticide treated curtains and insecticide treated covers
Description: The study is comparing the introduction of two new vector control tools (insecticide treated curtains and insecticide treated covers) through two different distribution strategies. These tools are curently not in use in the routine programmes of the concerned countries.
Study NCT03976206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Very small embryonic-like stem cell
Description: We carried out the subdermal application of VSELs with a 1-mL syringe (volume, 0.4 mL) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
Study NCT04038450 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No interventions separated the groups. Each group reviewed pictures and wrote down their estimated ROM of the joint pictured.
Study NCT01195324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin/Warfarin
Description: Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6 followed 14 days later by Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1
Study NCT01195324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin/Warfarin
Description: Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1 followed 14 days later by Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6
Study NCT01973413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabetes Assistant (DiAs)
Description: The Control-to-Range (CTR) algorithm that will be used in DiAs will automatically adjusts insulin delivery in response to CGM values that have exceeded or are predicted to exceed the bounds of a pre-specified blood glucose range.
Study NCT01973413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem t:slim Insulin Pump
Description: FDA, market-approved insulin pump.
Study NCT01973413 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Tandem t:slim Insulin Pump
Description: FDA, market-approved insulin pump.
Study NCT01973413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G4 Platinum sensor
Description: FDA, market-approved continuous glucose monitor (CGM)
Study NCT01973413 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dexcom G4 Platinum sensor
Description: FDA, market-approved continuous glucose monitor (CGM)
Study NCT01189981 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: One health conversation at baseline
Study NCT01189981 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eHealth intervention
Description: SMS based encouragements to intensive exercise
Study NCT01189981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth intervention
Description: SMS based encouragements to intensive exercise
Study NCT00573014 — intervention group
Intervention type: OTHER
Intervention: Cervical Spine Clearance
Description: All OBTPs with gross movement of all four extremities admitted to MetroHealth Medical Center who underwent a CT CS at MHMC between October 2006 and September 2008 will be included. Prospective data will be collected on these patients including age, gender, mechanism of injury, Glasgow Coma Scale (GCS) on admission, results of CT CS, GCS at the time of collar clearance, day of collar clearance, collar complications, date of reexamination, and results of reexamination. We will define an obtunded patient as a patient who was unable to reliably describe the presence or absence of CS symptoms in the opinion of the examining physician. Patients needed to have gross movement of all four extremities to be included in the study. We defined cervical collar complications as skin breakdown identified either by the skin care team during weekly rounds in the intensive care unit or by the treating physician at any time.
Study NCT02249039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intermittent IV CLON
Description: Mechanically ventilated infants and children receive intravenous intermittent Clonidine instead of dexmedetomidine
Study NCT05636761 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Heart rate variability
Description: Collection and Analysis of Heart Rate Variability
Study NCT03162419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
Study NCT03162419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
Study NCT03162419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Exchange
Description: High volume plasma exchange sessions till a maximum of ten sessions.
Study NCT03162419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCSF
Description: The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28
Study NCT00274677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Experimental treatment arm
Study NCT00274677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lamotrigine
Description: Experimental treatment
Study NCT03250208 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Participants randomized to the intervention group will receive Women's Fem Dophilus ® by Jarrow Formulas.
Study NCT03250208 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the control group will receive a placebo containing no active ingredients
Study NCT00685789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture, deqi
Description: Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the deqi sensation.
Study NCT00685789 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture Non-manipulation
Description: After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
Study NCT02356289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02356289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYK-461
Study NCT02681289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early goal directed neuromotor therapy
Description: Early goal directed neuromotor therapy (NGDT) is referred to as 'task-oriented' and is built on contemporary system theories of motor control. The development and learning of new skills occur in an interaction between the child, the task to be performed and the particular environment in which the activity takes place.